about
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's...
Read More
44.74
1.13
(2.59%)
175.4K
XNAS Volume
XNAS 06 Aug, 2026 11:44 AM (EDT)
Board Meeting
The next board meeting for Kodiak Sciences Inc is on 13 Aug 2026 for the purpose of Kodiak Sciences Inc Second Quarter Earnings Results for 2026
See details
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Kodiak Sciences Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..